Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.560
-0.060 (-3.70%)
At close: Mar 18, 2026, 4:00 PM EDT
1.550
-0.010 (-0.62%)
After-hours: Mar 18, 2026, 7:51 PM EDT
Lexicon Pharmaceuticals Revenue
In the year 2025, Lexicon Pharmaceuticals had annual revenue of $49.80M with 60.24% growth. Lexicon Pharmaceuticals had revenue of $5.49M in the quarter ending December 31, 2025, a decrease of -79.31%.
Revenue (ttm)
$49.80M
Revenue Growth
+60.24%
P/S Ratio
13.27
Revenue / Employee
$614,852
Employees
81
Market Cap
660.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 49.80M | 18.72M | 60.24% |
| Dec 31, 2024 | 31.08M | 29.88M | 2,481.48% |
| Dec 31, 2023 | 1.20M | 1.07M | 766.19% |
| Dec 31, 2022 | 139.00K | -159.00K | -53.36% |
| Dec 31, 2021 | 298.00K | -23.70M | -98.76% |
| Dec 31, 2020 | 24.00M | -298.08M | -92.55% |
| Dec 31, 2019 | 322.07M | 258.86M | 409.54% |
| Dec 31, 2018 | 63.21M | -28.48M | -31.06% |
| Dec 31, 2017 | 91.69M | 12.43M | 15.69% |
| Dec 31, 2016 | 79.26M | -50.76M | -39.04% |
| Dec 31, 2015 | 130.01M | 107.16M | 468.89% |
| Dec 31, 2014 | 22.85M | 20.63M | 928.53% |
| Dec 31, 2013 | 2.22M | 1.13M | 104.04% |
| Dec 31, 2012 | 1.09M | -760.00K | -41.10% |
| Dec 31, 2011 | 1.85M | -3.06M | -62.33% |
| Dec 31, 2010 | 4.91M | -5.79M | -54.13% |
| Dec 31, 2009 | 10.70M | -21.62M | -66.89% |
| Dec 31, 2008 | 32.32M | -17.80M | -35.51% |
| Dec 31, 2007 | 50.12M | -22.68M | -31.15% |
| Dec 31, 2006 | 72.80M | -2.88M | -3.81% |
| Dec 31, 2005 | 75.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 418.63M |
| Gyre Therapeutics | 116.59M |
| Theravance Biopharma | 80.33M |
| Prime Medicine | 4.63M |
| ProKidney | 744.00K |
LXRX News
- 7 days ago - Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes - GlobeNewsWire
- 13 days ago - Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates - GlobeNewsWire
- 15 days ago - Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences - GlobeNewsWire
- 20 days ago - Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 - GlobeNewsWire
- 5 weeks ago - Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - GlobeNewsWire
- 6 weeks ago - Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - GlobeNewsWire
- 6 weeks ago - Lexicon Announces Proposed Public Offering of Common Stock - GlobeNewsWire